Hunter James Randolph Jr 4

What Happened

• Hunter James Randolph Jr., a director of Tonix Pharmaceuticals (TNXP), was granted a derivative award of 22,700 option units on 2026-05-12. The filing reports an acquisition price of $0.00 (no cash paid at grant). This was a grant/award (transaction code A), not an open-market purchase or sale. The award does not represent immediately owned common shares until any options are exercised.

Key Details

• Transaction date: 2026-05-12; Form 4 filed: 2026-05-14 (appears timely).
• Transaction type: Grant/Award of derivative securities (option grant), reported as A.
• Quantity: 22,700 option units; reported acquisition price: $0.00.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Vesting: The option vests on the earlier of the one-year anniversary of the grant date and the Issuer’s 2027 Annual Meeting of Stockholders (per footnote).
• Insider role/status: Director; no 10% owner status indicated in the summary.

Context

• This filing documents an option grant under Tonix’s 2026 Stock Incentive Plan. Option grants are a form of compensation and do not involve immediate cash proceeds or share sales; the grantee must wait for vesting and then exercise (if desired) to convert options into shares. The filing is informational and does not itself indicate buying or selling pressure in the market.